Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection (ChikVIH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02553369|
Recruitment Status : Completed
First Posted : September 17, 2015
Last Update Posted : July 26, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Late 2013, the first indigenous cases of chikungunya have been observed in the French Antilles. At the end of May 2014, almost all of the islands of the Caribbean were affected by the outbreak.
During the large epidemic which affected the Island of La Réunion in 2005/2006, the attack rate was 38%. The most active period was three months.
In this context, knowledge of the attack rate and the epidemic in the Caribbean is an important issue for outbreak management and modeling work.
As the chikungunya virus had never circulated in the Caribbean, determining the seroconversion rate can be achieved by realizing a seroprevalence survey among the general population at the end of the outbreak. Another simple method is to estimate the rate in a cohort of patients followed regularly and whose habitat is distributed throughout the territory studied.
The follow up of patients infected by the human immunodeficiency virus (HIV) in the French West Indies is almost exclusively performed in hospitals in department of Infectious and Tropical Diseases.The high prevalence of HIV and homogeneous distribution of infected patients on all of our territories, allow to hypothesize that the risk of transmission of arboviruses by exposure to mosquito bites is comparable to the general population. This patient cohort is well suited to study the emergence of Chikungunya in the French West Indie .
Primary objective :
To estimate the cumulative incidence at the end of the first Chikungunya outbreak in the French West Indies by estimating the prevalence of specific antibodies of chikungunya virus in a sample (randomly constituted) from patients infected by HIV and representative of the general population of Martinique and Guadeloupe
Secondary objective :
To estimate the frequency of asymptomatic infections by the chikungunya virus in the studied population To estimate the frequency of chronic forms of chikungunya in the studied population
|Condition or disease||Intervention/treatment|
|HIV Infections Chikungunya Virus Infection||Other: Biological sample collection|
|Study Type :||Observational|
|Actual Enrollment :||388 participants|
|Official Title:||Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection|
|Study Start Date :||February 2015|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||April 2016|
Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
Other: Biological sample collection
A blood sample is collected during a follow up visit for HIV infection.
- Presence or not of chikungunya virus-specific immunoglobulin G antibodies (Elisa test) [ Time Frame: 1 day ]Presence or not of chikungunya virus-specific immunoglobulin G antibodies
- Change From Baseline in Pain [ Time Frame: 6 , 12 , 18 months after the first symptoms of chikungunya virus infection ]Score range from 0 (No pain) to 10 (worst possible pain)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Probability Sample|
- Adult (> 18 years old)
- Followed for HIV infection at the 2 investigators centers (1 located at Martinique and 1 at Guadeloupe)
- resident in Martinique /Guadeloupe ( French West Indies)
- informed consent signed by the patient
- patient who lived more than 6 month in an risk area for chikungunya virus infection
- patient with or documented chronic rheumatism
- patient who has received a blood transfusion during year 2013 or patient who is supposed to receive a blood transfusion during the study
- patient who has planned to live outside French West Indies during the follow up period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02553369
|CHU de Guadeloupe|
|Pointe-à-Pitre, Guadeloupe, France, 97159|
|Centre Hospitalier Universitaire de Fort-de-France|
|Fort-de-France, Martinique, France, 97200|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||University Hospital Center of Martinique|
|Other Study ID Numbers:||
2014-A01504-43 ( Registry Identifier: ID RCB )
2014/82 ( Registry Identifier: N° CPP )
|First Posted:||September 17, 2015 Key Record Dates|
|Last Update Posted:||July 26, 2016|
|Last Verified:||July 2016|
Acquired Immunodeficiency Syndrome
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
RNA Virus Infections
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Vector Borne Diseases